Related Experiment Video
Updated: Jul 3, 2026

Measuring Nucleotide Binding to Intact, Functional Membrane Proteins in Real Time
Published on: March 11, 2021
Is ATP binding responsible for initiating drug translocation by the multidrug transporter ABCG2?
Christopher A McDevitt1, Emily Crowley, Gemma Hobbs
1Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford, UK.
Abstract:
ABCG2 confers resistance to cancer cells by mediating the ATP-dependent outward efflux of chemotherapeutic compounds. Recent studies have indicated that the protein contains a number of interconnected drug binding sites. The present investigation examines the coupling of drug binding to ATP hydrolysis. Initial drug binding to the protein requires a high-affinity interaction with the drug binding site, followed by transition and reorientation to the low-affinity state to enable dissociation at the extracellular face. [3H]Daunomycin binding to the ABCG2 R482G isoform was examined in the nucleotide-bound and post-hydrolytic conformations. Binding of [3H]daunomycin was displaced by ATP analogues, indicating transition to a low-affinity conformation prior to hydrolysis. The low-affinity state was observed to be retained immediately post-hydrolysis. Therefore, the dissociation of phosphate and/or ADP is likely to be responsible for resetting of the transporter. The data indicate that, like ABCB1 and ABCC1, the 'power stroke' for translocation in ABCG2 R482G is the binding of nucleotide.
Insights
Drug binding to ABCG2 transporters initiates a conformational change, enabling chemotherapy efflux. Nucleotide binding, not hydrolysis, drives the transporter's "power stroke" for drug translocation.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- ABCG2 (ATP-binding cassette sub-family G member 2) is a transporter protein.
- It confers cancer cell resistance by effluxing chemotherapeutic drugs.
- ABCG2 possesses interconnected drug binding sites, influencing its function.
Purpose of the Study:
- To investigate the coupling mechanism between drug binding and ATP hydrolysis in ABCG2.
- To elucidate the role of nucleotide binding in the transporter's conformational changes and drug translocation.
Main Methods:
- Utilized [3H]Daunomycin binding assays.
- Examined the ABCG2 R482G isoform in nucleotide-bound and post-hydrolytic states.
- Assessed the effect of ATP analogues on drug binding.
Main Results:
- Initial drug binding involves a high-affinity interaction, transitioning to a low-affinity state.
- ATP analogues displaced [3H]Daunomycin, indicating a pre-hydrolysis transition to low affinity.
- The low-affinity state persisted immediately post-ATP hydrolysis, suggesting phosphate/ADP dissociation resets the transporter.
Conclusions:
- Nucleotide binding, rather than hydrolysis, is the primary driver ('power stroke') for drug translocation in ABCG2 R482G.
- This mechanism is similar to other ABC transporters like ABCB1 and ABCC1.
- Understanding these dynamics is crucial for developing strategies to overcome chemotherapy resistance.
Related Concept Videos
ABC Transporters: Exporter
Carrier-Mediated Transport
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
ABC Transporters: Importer
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
Active Transport
Primary active transporters, like Na+, K+ and -ATPase, directly utilize ATP to move ions across the membrane. These transporters play significant roles in various physiological processes. For instance, Na+, K+ and -ATPase maintain...
Drug Absorption Mechanism: Carrier-Mediated Membrane Transport
Facilitated diffusion is a passive process that utilizes human Solute Carrier (SLC) transporters. These transporters bind to the drug, undergo structural...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

